`
`Filed: April 28, 2017
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`————————————————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`————————————————
`
`MYLAN PHARMACEUTICALS INC.
`
`Petitioner,
`
`v.
`
`YEDA RESEARCH & DEVELOPMENT CO., LTD.
`
`Patent Owner.
`
`————————————————
`Case No. IPR2017-00195 (9,155,776)
`————————————————
`
`MOTION TO TERMINATE PROCEEDINGS
`UNDER 35 U.SC. § 317(a)
`
`Pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. §§ 42.72, Petitioner Mylan
`
`Pharmaceuticals Inc. (“Mylan”) respectfully requests termination of IPR2017-
`
`00195.
`
`The Board authorized this Motion by email on April 27, 2017.
`
`Patent Owner does not oppose this Motion.
`
`Basis for Termination
`
`On January 30, 2017, the United States District Court for the District of
`
`Delaware held U.S. Patent No. 9,155,776, the patent that is the subject of this
`
`
`
`
`
`
`
`proceeding, invalid as obvious. Ex. 1068; Paper No. 6. The District Court reached
`
`this conclusion applying a higher evidentiary standard than would apply in this
`
`proceeding. In view of the District Court’s decision and to conserve the Board’s
`
`resources, Mylan respectfully requests termination of this proceeding.
`
`Mylan believes that termination of this proceeding is proper under 35 U.S.C.
`
`§ 317(a) because the Board has not yet decided the merits of the proceeding.
`
`Termination of this proceeding avoids both the Board and the parties from
`
`spending unnecessary resources.
`
`Status of Pending Patent Office Proceedings
`
`The Board has previously issued final written decisions in IPR2015-00643,
`
`IPR2015-00644 and IPR2015-00830 holding unpatentable three patents in the
`
`same family as the ’776 patent. Patent Owner has appealed these decisions to the
`
`Federal Circuit. Mylan is unaware of any other pending, related inter partes
`
`review proceedings.
`
`Status of Pending District Court Actions
`
`With respect to the related district court actions:
`
`1.
`
`Final judgment has been entered in In re Copaxone 40 mg
`
`Consolidated Cases, No. 14-cv-01171 (D. Del.) holding invalid U.S. Patent No.
`
`8,232,250, No. 8,399,413, No. 8,969,302, and No. 9,155,776. The case is currently
`
`on appeal to the Federal Circuit.
`
`2
`
`
`
`
`
`2.
`
`A joint stipulation has been filed to dismiss with prejudice the claims
`
`and counterclaims regarding U.S. Patent No. 9,402,874 in Teva Pharmaceuticals
`
`USA, Inc. v. Doctor Reddy’s Laboratories, Ltd., No. 16-cv-1267 (D. Del.) (Docket
`
`No. 72).
`
`* * *
`
`Accordingly, Mylan respectfully requests termination of this proceeding.
`
`
`
`Dated: April 28, 2017
`
`
`
`/Brandon M. White/
`
`
`
`Brandon M. White
`Reg. No. 52,354
`Perkins Coie LLP
`700 13th St., NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6206
`E-mail: bmwhite@perkinscoie.com
`
`Attorney for Mylan Pharmaceuticals Inc.
`
`3
`
`
`
`
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that the foregoing Motion to Terminate
`
`Proceedings Under 35 U.SC. § 317(a) was served electronically via email as
`
`follows:
`
`Elizabeth Holland
`eholland@goodwinprocter.com
`
`William James
`wjames@goodwinprocter.com
`
`
`
`Dated: April 28, 2017
`
`
`
`/Brandon M. White/
`Brandon M. White
`
`Attorney for Mylan Pharmaceuticals Inc.
`
`
`
`1
`
`